Oral Transmucosal Drugs Market Report 2026

The oral transmucosal drugs market size has grown strongly in recent years. It will grow from $43.21 billion in 2025 to $47.18 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to need for rapid onset pain management solutions, limitations of oral swallowing in critical patients, established clinical use of sublingual tablets, growth in opioid dependence treatments, preference for bypassing first-pass metabolism.

The oral transmucosal drugs market size is expected to see strong growth in the next few years. It will grow to $63.76 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to rising focus on fast-acting drug delivery, increasing neurological and chronic pain cases, growing demand for patient-centric dosage forms, innovation in mucoadhesive technologies, expansion of home-based and emergency care therapies. Major trends in the forecast period include growing adoption of rapid-acting drug delivery systems, increasing use of sublingual and buccal films, rising demand for non-invasive alternatives to injections, expansion of transmucosal therapies for pain and neurological disorders, improved patient compliance through easy-to-administer formats.

The increasing prevalence of Parkinson’s disease is anticipated to drive the expansion of the oral transmucosal drug market in the coming years. Parkinson’s disease is a progressive neurological condition marked by tremors, stiffness, and slowed movement due to the deterioration of dopamine-producing neurons in the brain. The growth in Parkinson’s cases is attributed to aging populations, environmental factors, genetic predisposition, and enhanced diagnostic methods that facilitate earlier detection. Oral transmucosal drug delivery aids in managing Parkinson’s disease by allowing rapid absorption through the oral mucosa, avoiding gastrointestinal delays, and offering quicker relief during “off” episodes when conventional oral tablets may be less effective. For example, in January 2023, the American Parkinson Disease Association (APDA), a U.S.-based non-profit organization, reported that a new epidemiological study identified nearly 90,000 new Parkinson’s diagnoses annually in the United States, representing a 50% increase compared to 2022. Consequently, the rising prevalence of Parkinson’s disease is supporting the growth of the oral transmucosal drug market.

Major companies in the oral transmucosal drug market are concentrating on developing innovative solutions such as sublingual tablets to promote rapid drug absorption and enhance treatment adherence. Sublingual tablets are medications formulated to dissolve beneath the tongue, enabling the drug to enter the bloodstream directly for a quicker therapeutic effect. For example, in June 2024, Aquestive Therapeutics Inc., a US-based pharmaceutical firm, obtained approval from the U.S. Food and Drug Administration (FDA) for Libervant (diazepam) Buccal Film for the acute management of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters) in epilepsy patients aged 2 to 5 years. This thin, fast-dissolving film is placed inside the cheek, where it adheres securely and delivers a precise dose of diazepam rapidly and reliably. This convenient, noninvasive treatment option provides superior usability and fast absorption, offering an effective and discreet method to manage acute repetitive seizures in young pediatric patients.

In January 2024, XOMA Corporation, a biotechnology company based in the US, acquired DSUVIA from Talphera, Inc. for $8 million. Through this acquisition, XOMA aims to optimize revenue from DSUVIA, a sufentanil sublingual tablet, while sharing profits and risks with Talphera and capitalizing on potential milestones from Alora Pharmaceuticals. Talphera Inc. is a US-based pharmaceutical company engaged in the development of oral transmucosal drugs.

Major companies operating in the oral transmucosal drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi-Aventis LLC, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly & Company Ltd., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Actavis Pharma Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Endo Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Mallinckrodt Pharmaceuticals Plc, Glenmark Pharmaceuticals Limited, Jubilant Life Sciences Limited, Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd, Wockhardt Ltd.

North America was the largest region in the oral transmucosal drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral transmucosal drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral transmucosal drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the oral transmucosal drugs market by increasing costs of imported APIs, polymers, and specialized excipients used in films and sprays. These impacts are most evident in Asia-Pacific and European regions that rely heavily on cross-border pharmaceutical inputs. Higher production costs have affected pricing for advanced transmucosal formulations. However, tariffs have also encouraged local sourcing, domestic manufacturing investments, and supply chain diversification, supporting long-term market stability.

The oral transmucosal drugs market research report is one of a series of new reports that provides oral transmucosal drugs market statistics, including oral transmucosal drugs industry global market size, regional shares, competitors with a oral transmucosal drugs market share, detailed oral transmucosal drugs market segments, market trends and opportunities, and any further data you may need to thrive in the oral transmucosal drugs industry. This oral transmucosal drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oral transmucosal drugs are medications designed to be absorbed through the mucous membranes in the mouth, allowing for quick effects while bypassing the initial metabolism in the liver and gastrointestinal tract. These medications are often used for conditions that need fast relief, such as pain management, and for patients who have trouble swallowing pills.

The primary forms of oral transmucosal drugs include tablets, films, liquids and sprays, and other types. Tablets in oral transmucosal drug delivery are solid dosage forms designed for administration through the mucous membranes in the mouth. They are indicated for conditions such as opioid dependence, nausea and vomiting, erectile dysfunction, neurological disorders, and other disorders, and are administered via the sublingual mucosa, buccal mucosa, and other routes. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The oral transmucosal drugs market consists of sales of buccal patches, sublingual tablets, lozenges, and oral transmucosal powders. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.